Elevated transforming growth factor β and mitogen-activated protein kinase pathways mediate fibrotic traits of Dupuytren's disease fibroblasts
© Krause et al; licensee BioMed Central Ltd. 2011
Received: 12 March 2011
Accepted: 28 June 2011
Published: 28 June 2011
Dupuytren's disease is a fibroproliferative disorder of the palmar fascia. The treatment used to date has mostly been surgery, but there is a high recurrence rate. Transforming growth factor β (TGF-β) has been implicated as a key stimulator of myofibroblast activity and fascial contraction in Dupuytren's disease.
We studied Dupuytren's fibroblasts in tissues ex vivo and in cells cultured in vitro and found increased TGF-β expression compared to control fibroblasts. This correlated not only with elevated expression and activation of downstream Smad effectors but also with overactive extracellular signal-regulated kinase 1/2 (ERK1/2)/mitogen-activated protein (MAP) kinase signalling. Treatment with the TGF-β type I receptor kinase inhibitor SB-431542 and bone morphogenetic protein 6 (BMP6) led to inhibition of elevated Smad and ERK1/2/MAP kinase signalling as well as to inhibition of the increased contractility of Dupuytren's fibroblasts. BMP6 attenuated TGF-β expression in Dupuytren's fibroblasts, but not in control fibroblasts. Platelet-derived growth factor (PDGF) expression was strongly promoted by TGF-β in Dupuytren's fibroblasts and was curbed by SB-431542 or BMP6 treatment. High basal expression of phosphorylated ERK1/2 MAP kinase and fibroproliferative markers was attenuated in Dupuytren's fibroblasts by a selective PDGF receptor kinase inhibitor. Cotreatment of Dupuytren's fibroblasts with SB-431542 and the mitogen-activated protein kinase kinase 1 inhibitor PD98059 was sufficient to abrogate proliferation and contraction of Dupuytren's fibroblasts.
Both TGF-β and ERK1/2 MAP kinase pathways cooperated in mediating the enhanced proliferation and high spontaneous contraction of Dupuytren's fibroblasts. Our data indicate that both signalling pathways are prime targets for the development of nonsurgical intervention strategies to treat Dupuytren's disease.
Dupuytren's disease (DD) is a common fibroproliferative condition that only affects the hand. The characteristic feature is a progressive contracture of the palm and fingers. Patients commonly first display a nodule in the palm or on the volar (palmar) aspect of the fingers caused by a thickened layer of tissue (palmar fascia) between the skin and the tendons of the hand and fingers. The nodule is a key diagnostic feature and represents the early proliferative stage of the disease. The nodules contain mostly myofibroblasts [1, 2]. As the disease progresses, the nodules may disappear and give way to the formation of cords. These cords represent characteristics of fibrosis within the involutional and residual stages of the disease and comprise mostly fibroblasts and extracellular matrix (ECM).
Treatment of DD consists largely of surgical excision of the contracted tissue. Because of high recurrence rates following surgery, investigations are underway to determine the underlying causes of DD to optimise treatment strategies [1, 2]. The myofibroblast, a specialised fibroblast phenotype that expresses α-smooth muscle actin (α-SMA), provides the cell with contractile activity [3–5]. To date, many growth factors have been implicated in Dupuytren's contracture; transforming growth factor β (TGF-β) in particular has been proposed to play a prominent role .
TGF-β is a member of a protein family that also includes activins, nodal and bone morphogenetic proteins (BMPs). TGF-β protein family members signal through type I and type II serine/threonine kinase receptors . Type I receptors are also called 'activin receptor-like kinases' (ALKs). ALK4, ALK5 and ALK7 are type I receptors of activin, TGF-β and nodal protein kinases, respectively. SB-431542 is a selective inhibitor of ALK4, ALK5 and ALK7 kinase activity . Signalling from activated type I receptors is mainly transduced into the cytoplasm through phosphorylation of receptor-regulated Smads (R-Smads). Activated ALK4, ALK5 and ALK7 induce phosphorylation of Smad2 and Smad3. BMPs mediate the activation of Smad1, Smad5 and Smad8. Activated R-Smads form heteromeric complexes with Smad4 that accumulate in the nucleus, where they regulate gene expression, including plasminogen activator inhibitor 1 (PAI-1; also known as SERPINE1, a TGF-β/ALK5 target gene) and the inhibitor of DNA binding 1 gene (a BMP target gene) . TGF-β can also activate non-Smad pathways, including the extracellular signal-regulated kinase (ERK) mitogen-activated protein (MAP) kinase signalling pathway [9, 10]. TGF-β is a potent modulator of fibroblast and myofibroblast proliferation and differentiation [3, 11–13]. Previous studies of DD tissue found increased protein synthesis and expression of all three TGF-β isoforms and their receptors [14–18]. In vitro contraction assays revealed that TGF-β stimulation generates or increases contractile force in Dupuytren-derived cells [19–23]. In addition, TGF-β stimulation leads to upregulation of key ECM components, such as fibronectin and type I collagen (COL1), and this effect either may be direct or may occur indirectly via enhanced expression of matricellular protein connective tissue growth factor (CTGF/CCN2) [24, 25]. TGF-β stimulation can also induce the expression of growth factors, such as platelet-derived growth factor (PDGF) .
It is not known whether BMPs play a role in DD. Compared to normal fascia-derived cells, Dupuytren-derived cells do not express BMP4 and exhibit decreased BMP6 and BMP8 expression . A previous study found that there is decreased BMP receptor expression and, apparently, reduced BMP responsiveness in DD tissue, which has constrained research into BMPs as potential antagonists of TGF-β-induced fibrosis in DD as described in kidney and liver fibrosis .
In this study, we investigated the aberrant activation of the TGF-β/Smad and PDGF/ERK1/2/MAP kinase pathways in DD tissue specimens and cell culture. Using BMP6 and selective chemical inhibitors of the TGF-β receptors, the PDGF receptors and the MAP kinase pathway, we attempted to counteract the fibrogenic characteristics of DD. Our insights may contribute to the development of new therapeutic strategies for sustained, nonsurgical treatment of DD.
DD tissue specimens were obtained from four adult patients undergoing fasciectomy for DD. Patients who underwent carpal tunnel release and showed no evidence of DD contributed the control tissue from normal palmar fascia (n = 3) or carpal ligament (n = 1). All DD tissues used were from primary releases. The tissue was separated macroscopically in nodules and cords. Only nodules were used in this study. For details on how samples were prepared, see the Additional files.
Clinical sample preparation
After excision, the nodule was divided in three portions. One portion was placed in 10% formalin and further processed for immunohistochemistry. The second was immediately placed into liquid nitrogen for protein extraction. The third portion was used for primary cell culture. All of the patients underwent excision independently of this study and had not undergone previous surgery on their hands. Oral consent for removal of the tissue and storage in the tissue bank for research purposes was obtained from the patients. Individual consent for this specific project was waived by the local ethics committee because the research was performed on 'waste' material, which was stored in a coded fashion.
Recombinant human TGF-β3 (OSI Pharmaceuticals Inc., Melville, NY, USA) and recombinant human BMP6 (Creative BioMolecules, Hopkinton MA, USA) were generously provided by K Iwata and K Sampath, respectively. SB-431542 compound, which targets ALK4, ALK5 and ALK7, was purchased from Tocris Bioscience, Ellisville, Missouri, USA. The PD98059 compound, which targets mitogen-activated protein kinase kinase 1 (MEK1), was purchased from Cell Signaling Technology (Danvers, MA, USA). The vascular endothelial growth factor (VEGF) receptor inhibitor PTK787/ZK222584, the epidermal growth factor (EGF) receptor inhibitor PKI166 and the PDGF receptor inhibitor STI571 (also known as imatinib mesylate) were kindly provided by Novartis, Amsterdam, The Netherlands. The protein kinase C activator 12-O-tetradecanoyl-phorbol-13-acetate (TPA) was obtained from Sigma (Sigma Chemical Co., St. Louis, MO, USA).
To obtain primary cells, tissues were minced under sterile conditions into pieces that measured approximately 1 × 1 × 2 mm3. Ten to twenty pieces were placed as explants into the wells of six-well plates and stored in 37°C incubators in 5% CO2. Primary cells from passages 3 through 6 were used for the experiments. All of the cells were subcultured in DMEM containing 4.5 g/L glucose (Gibco, Breda, The Netherlands) supplemented with 10% foetal bovine serum (FBS) (Integro, Zaandam, The Netherlands), 100 IU/mL penicillin and 100 IU/mL streptomycin (Invitrogen, Breda, The Netherlands).
RNA isolation and quantitative real-time PCR
Total RNA was extracted by using the RNeasy Kit (Qiagen, Venlo, The Netherlands) according to the manufacturer's instructions. Reverse transcriptase PCR was performed using the RevertAid H Minus First Strand cDNA Synthesis Kit (Fermentas, St. Leon-Rot, Germany) according to the manufacturer's instructions. All of the samples were plated in duplicate, and TaqMan PCR reactions were performed using the StepOnePlus Real-Time PCR System (Applied Biosystems, Carlsbad, California, USA). Lack of DNA contamination was verified and gene expression levels were determined using the comparative ΔCt method with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as the reference.
Quantitative PCR primers
Human TGF-β1 through TGF-β3, α-SMA, PAI-1, c-myc, COl1A2, fibronectin, Smad1 through Smad3, CTGF, PDGF-A, PDGF-B and GAPDH gene expression was analysed using the following forward and reverse primers: TGF-β1, 5'-CTCTCCGACCTGCCACAGA-3' and 5'-AACCTAGATGGGCGCGATCT-3'; TGF-β2, 5'-CCGCCCACTTTCTACAGACCC-3' and 5'-GCGCTGGGTGGGAGATGTTAA-3'; TGF-β3, 5'-CTGGCCCTGCTGAACTTTG-3' and 5'-AAGGTGGTGCAAGTGGACAGA-3'; α-SMA, 5'-CACCTTCCAGCAGATGTGGAT-3' and 5'-AAGCATTTGCGGTGGACAAT-3'; PAI-1, 5'-TCTTTGGTGAAGGGTCTGCT-3' and 5'-CTGGGTTTCTCCTCCTGT TG-3'; c-myc, 5'-CGTCTCCACACATCAGCACAA-3' and 5'-CACTGTCCAACTTGACCCTCTTG-3'; COl1A2, 5'-GATGTTGAACTTGTTGCTGAGG-3' and 5'-TCTTTCCCCATTCATTTGTCTT-3'; fibronectin, 5'-GAGGCCACCATCACTGGTT-3' and 5'-AGTGCGATGACATAGATGGTGTA-3'; Smad1, 5'-TGAACCATGGATTTGAGACAGT-3' and 5'-CTGGCGGTGGTATTCTGC-3'; Smad2, 5'-CGAAAAGGATTGCCACATGTT-3' and 5'-TTGAGTTCATGATGACTGTGAAGATC-3'; Smad3, 5'-CGGTCAACCAGGGCTTTG-3' and 5'-CAGCCTTTGACGAAGCTCATG-3'; CTGF, 5'-TTGCGAAGCTGACCTGGAAGAGAA-3' and 5'-AGCTCGGTATGTCTTCATGCTGGT-3'; PDGF-A, 5'-CCTCACATCCGTGTCCTCTT-3' and 5'-ACACGAGCAGTGTCAAGTGC-3'; PDGF-B, 5'-TGCTGTTGAGGTGGCTGTAG-3' and 5'-GAAAATGCAGGGTGGAGGTA-3'; TGF-α, 5'-TAACCACGAGACCCTCAACC-3' and 5'-CCCAAGCCTTAGCTGTCTTG-3'; and GAPDH, 5'-ATCACTGCCACCCAGAAGAC-3' and 5'-ATGAGGTCCACCACCCTGTT-3'.
MTS-based proliferation assay
Cells were seeded into 96-well plates at 7 × 103 cells/well and treated the next day with the indicated inhibitors or DMSO as a control. Increases in the number of viable cells after culture were measured daily for 4 days using an 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)-based proliferation assay according to the manufacturer's instructions (CellTiter 96 AQueous One Solution Cell Proliferation Assay System; Promega, Leiden, The Netherlands) and using the measured absorbance at 490 nm on day 0 as the reference.
Tissue lysate preparation and Western blot analysis
For tissue lysates, biopsies were frozen in liquid nitrogen and pulverised using a mortar. Thereafter, the triturated tissues were incubated in ice-cold lysis buffer (150 mmol NaCl, 20 mmol Tris·HCl, pH 7.5, 1% Nonidet P-40, 5 mmol sodium ethylenediaminetetraacetic acid (EDTA) and one Complete Protease Inhibitor Cocktail Tablet (Roche, Woerden, The Netherlands) per 50 mL of solution) for 30 minutes. Prior to centrifugation at 4°C for 15 minutes at 14 × 103 rpm, the samples underwent extensive vortexing and sonification. The total protein content of the supernatant was determined using the DC Protein Assay (Bio-Rad Laboratories, Veenendaal, The Netherlands)). Equal amounts of total protein (100 μg/μL) were loaded onto a 10% gel, followed by SDS-PAGE and Western blot analysis. For cell-based assays, cells were plated onto six-well plates at a density of 4 × 105 cells/well, stimulated with the indicated reagents and directly lysed in sample buffer (250 mmol Tris·HCl, pH 6.8, 8% SDS, 40% glycerol, 5% β-mercaptoethanol, and bromophenol blue) after 18 hours. Antibodies specifically targeting Smad1 (Zymed, San Francisco, CA, USA), Smad2/3 (BD Transduction Laboratories, Breda, The Netherlands), phosphorylated ERK1/2 (P-ERK1/2; Cell Signaling Technology), PAI-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), Col1α 2 (Col1A2; SouthernBiotech, Birmingham, Alabama, USA), α-SMA (Sigma Chemical Co.), fibronectin/ED-A (Abcam, Cambridge, MA, USA) and c-myc (Santa Cruz Biotechnology) were purchased. Antibodies targeting phosphorylated Smad1 and Smad2 (P-Smad1 and P-Smad2, respectively) were described previously . P-Smad3 was obtained from E Leof (Mayo Clinic, Rochester, MN, USA), and P-ERK1/2 antibodies were a gift from WH Moolenaar (Netherlands Cancer Institute, Amsterdam, The Netherlands). Equal loading was confirmed using an anti-β-actin antibody (Sigma Chemical Co.). Quantitative Western blot analysis was performed using secondary goat anti-rabbit IRDye 680 and goat anti-mouse IRDye 800 CW with the Odyssey Scanner (LI-COR Biosciences, Lincoln, Nebraska USA) according to the manufacturer's instructions.
For immunofluorescence staining, cells were grown on coverslips overnight. Cells were fixed with ice-cold methanol for 30 minutes, washed twice with PBS, quenched with 20 mmol NH4Cl, and permeabilised with 0.1% Triton X-100 the following day. Cells were then incubated in blocking solution (PBS containing 3.0% BSA) for 45 minutes followed by incubation for 1 hour with anti-α-SMA antibody (Sigma Chemical Co.) diluted 1:100 in blocking solution. After washing, the labelled secondary antibody Alexa Fluor 488 goat anti-mouse immunoglobulin G (IgG) (Invitrogen) was used. Nuclei were stained using Hoechst 33258 (Invitrogen) according to the manufacturer's instructions. Specimens were visualised by using an Olympus IX51 inverted microscope at ×100 magnification using the cellF Soft Imaging System (Olympus, Zoeterwoude, The Netherlands).
Cells were cultured overnight on coverslips. The next day fixation in acetone followed by staining for α-SMA (α-SMA/1, M851, 1A4 clone; Dako, Carpinteria, CA, USA) at 1:500 dilution was performed for 60 minutes. Endogenous peroxidase was quenched with 0.1% natriumazide/0.3% hydrogen peroxide in PBS. After post-antibody blocking, goat poly-horseradish peroxidase (HRP) anti-mouse IgG (Immunologic, Duiven, The Netherlands) was added for 30 minutes. The colouring reaction was developed with 3-amino-9-ethylcarbazole (AEC), and counterstaining was performed with H & E.
Paraffin-embedded tissue samples of 5-μm thickness were sequentially cut. Before blocking endogenous peroxidase activity with 1% hydrogen peroxide (Merck, Amsterdam, The Netherlands) in 2% PBS, sections were deparaffinised and rehydrated using xylene and a descending alcohol series. Blocking was performed with the following sequence: 2.5% periodic acid, 0.02% sodium borohydride and Protein Block (Dako).
Detection of TGF-β3: After deparaffinisation, antigen retrieval was performed in citrate buffer. Blocking was done with Protein Block (Dako) for 20 minutes. TGF-β3 antibody (Abcam) was applied overnight in a humid chamber at 4°C. Slides were rinsed in PBS, after which biotinylated link antibody was added (LSAB2 System; Dako) for 60 minutes. After slides were washed in PBS, streptavidin conjugate (LSAB2 System) was applied for 60 minutes.
Detection of P-Smad2: Prior to the application of Protein Block for 20 minutes, sections were pretreated with proteinase K (2 μg/mL in PBS) at 37°C for 30 minutes. P-Smad2 (Ser465/467; Cell Signaling Technology) was added overnight in a humid chamber at 4°C. Slides were rinsed in PBS, after which biotinylated link antibody was added (LSAB2 System) for 60 minutes. After PBS washing, streptavidin conjugate (LSAB2 System) was applied for 60 minutes.
Detection of α-SMA: After quenching endogenous peroxidase activity with 0.3% H2O2 in methanol, slides were heated in Tris-EDTA for 10 minutes at 100°C for antigen retrieval. The α-SMA antibody (α-SMA/1, M851, 1A4 clone; Dako, Glostrup, Denmark) was applied for 60 minutes followed by post-antibody blocking (Immunologic) for 15 minutes. After rinsing, goat poly-HRP against mouse IgG (Immunologic) was added for 30 minutes followed by PBS washing. All colouring reactions were developed by using 3,3'-diaminobenzidine (Sigma Chemical Co.) followed by counterstaining with H & E. Unlabelled samples were scored by an independent pathologist. Scoring was rated as follows: no staining (-) (except for staining in blood vessel walls), weak staining (+), moderate staining (++) and intense staining (+++).
Detection of P-ERK1/2: Before blocking endogenous peroxidase activity with 40% methanol and 1% H2O2 (Merck) in PBS, sections were deparaffinised and rehydrated using xylene and a descending alcohol series. Antigen retrieval using proteinase K (2.5 μL in 100 mmol Tris, pH 9.0, and 50 mmol EDTA, pH 8.0) for 10 minutes at 37°C was followed by three washes with 0.1 mol Tris-buffered saline (pH 7.4) containing 0.02% Tween 20 (TBST). Thereafter slides were incubated in 0.5% (Boehringer, Ingelheim, Germany) blocking reagent (BMP) in TBST for 60 minutes at 37°C. Subsequently, the P-ERK1/2 antibody (1:100; Cell Signaling Technology) diluted in 0.5% BMP/TBST was applied overnight at 4°C. Next, a species-specific biotinylated anti-IgG antibody (1:600 dilution in 0.5% BMP/TBST) was applied, followed by 45 minutes at 37°C. Incubation with streptavidin-HRP (1:200 dilution in 0.5% BMP/TBST) for 30 minutes at 37°C preceded and followed an amplification step using biotinyl-tyramide. Staining was carried out using AEC (Sigma Chemical Co., Zwijndrecht, The Netherlands) and Mayer's haematoxylin (Merck) according to the manufacturers' instructions. A water-based mounting solution was applied, and staining was visualised by using an Olympus IX51 inverted microscope equipped with the cellF Soft Imaging System (Olympus). Unlabelled samples were scored by an independent researcher.
Fibroblast-populated collagen lattice contraction assay
Three-dimensional fibroblast-populated collagen lattice (FPCL) contraction assays were carried out with primary cell cultures from passages 4 through 6. The assay was performed as described previously by others, with some modifications [30–32]. The collagen lattices were prepared by mixing a neutralising solution of COL1 (eight parts 3 mg/mL COL1 (PurCol®, Daiichi Sankyo, Parsippany, New Jersey, USA) one part 10 × α-MEM (Invitrogen) and one part HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) buffer, pH 9.0). Final collagen and cell concentrations were adjusted to 2 mg/mL and 86 × 103 cells/mL using PBS, respectively. The cell-collagen mixture was aliquoted into PBS + 2% BSA-pretreated 24-well culture dishes (0.5 mL/well) and left to polymerise for 1 hour at 37°C. In each well, to the top of the polymerised lattice, we added 0.5 mL/well of DMEM containing 10% FBS. After 2 days of incubation at 37°C, the attached FPCLs were mechanically released from the sides of the culture plates, and fresh media supplemented with 0.5% FBS and the indicated substances were added. Images were obtained at various time points over a 5-day period using the Odyssey Scanner (LI-COR Biosciences). Collagen lattice areas were measured using the corresponding Odyssey 2.1 software.
Values are expressed as means ± standard error of the mean. For statistical comparisons of two samples, an unpaired, a two-tailed Student's t-test with distinction of equal and unequal variances in a group (Levene's test) was used to determine the significance of differences between means. In addition, a nonparametric Mann-Whitney U test under the null hypothesis that the distributions of both groups (control versus Dupuytren-derived fibroblasts) were equal was performed for the data set shown in Figure 2C. All of the relevant comparisons were considered to be significantly different at P < 0.05. Experiments were performed at least three times, and representative results are shown.
TGF-β/Smad signalling upregulated in DD
Overview of patients' details
Evaluation of immunohistochemical staininga
Tissue samples were further investigated for active TGF-β signalling and for protein expression of key ECM components induced during fibrogenesis (Figure 1B). On average, Smad2 and Smad3 protein expression levels were significantly upregulated in DD patients compared to β-actin protein expression levels. Furthermore, we detected an increase in P-Smad2, but not P-Smad3, when normalised to total Smad2 and Smad3, respectively, in DD patients versus controls (Figure 1B and Additional file 1, Supplementary Figure 1). In contrast, Smad1 protein expression levels did not differ between control and DD patient material. P-Smad1 was not detected in control or DD samples (data not shown). Fibrogenesis ECM markers, such as COL1 and fibronectin/ED-A, were detectable in DD tissue but not in control samples. The myofibroblast marker α-SMA was strongly upregulated in all four DD patients (Figure 1B).
We then quantitatively compared the mRNA expression levels of components involved in TGF-β signalling and fibrosis. On average, a nonparametric Mann-Whitney U test (data not shown) followed by an unpaired Student's t-test revealed that Smad2 and Smad3 mRNA expression, as well as expression of the TGF-β target genes PAI-1 and CTGF, were significantly upregulated in Dupuytren's fibroblasts compared to control fibroblasts. mRNA expression of the ECM component COL1, α2 (COL1A2) gene and the cytoskeleton representative α-SMA were also significantly increased, whereas the expression of fibronectin mRNA did not differ from that of control cells. The BMP signalling intracellular component Smad1 was present at lower levels in Dupuytren cells compared to normal fascia-derived cells (Figure 2C). The fact that the null hypothesis of the Mann-Whitney U test of equal distribution of control (patients 1 through 4) and Dupuytren-derived (patients 1 through 4) fibroblasts was rejected in 87.5% of the tested samples because we concluded that both control and Dupuytren-derived fibroblasts have an independent mRNA expression profile that also allows for statistical comparison, which furthermore allows the statistical analysis of pooled cell samples. Taken together, these results suggest that TGF-β/Smad signalling is increased in this fibroproliferative disease.
SB-431542 inhibited fibrogenic properties of Dupuytren's fibroblasts
BMP6 attenuated TGF-β signalling in Dupuytren's fibroblasts
Because it has been suggested that BMPs, particularly BMP7, can counteract TGF-β-induced fibrosis in the kidney, lung and liver, we investigated the effect of BMPs on Dupuytren's fibroblasts. BMP6, but not BMP7, attenuated endogenous TGF-β-like signalling. Quantitative PCR revealed that BMP6 strongly induced TGF-β1 mRNA expression in control cells but left the expression of the TGF-β2 and TGF-β3 isoforms unaffected (Figure 3A). In contrast to the control cells, in Dupuytren's fibroblasts BMP6 counteracted TGF-β1 and TGF-β3 mRNA expression (Figure 3A) and reduced SMAD2 and SMAD3, but not SMAD1, mRNA expression (data not shown).
As predicted on the basis of its antagonistic effects on TGF-β-like signalling, BMP6 (but not BMP7) attenuated α-SMA expression and counteracted the spontaneous elevated contraction seen in Dupuytren's fibroblasts (Figures 3B to 3D and Additional file 2, Supplementary Figure 2; data not shown). This inhibitory effect of BMP6 was further potentiated by simultaneous treatment with SB-431542 (Figures 3C and 3D and Additional file 2, Supplementary Figure 2).
ERK1/2/MAP kinase signalling elevated in DD
We next determined the direct effects of TGF-β on the phosphorylation of ERK1/2 in Dupuytren's fibroblasts. We found that 5 minutes of TGF-β3 treatment induced a further increase in the phosphorylation of ERK1/2, which was inhibited by SB-431542 to a level lower than the basal level (Figure 4C). The presence of BMP6, however, had only marginal effects on the direct TGF-β3-induced phosphorylation of ERK1/2 (Figure 4C). In addition to its direct effect, TGF-β3 also induced an increase in ERK1/2 phosphorylation after 18 hours of stimulation. Interestingly, while SB-431542 showed only marginal effects on this sustained activation, BMP6 strongly attenuated this effect after 18 hours (Figure 4C).
The sustained effect of TGF-β3 on ERK1/2 was likely indirect and may have occurred via the TGF-β-mediated induction of growth factors. Indeed, PDGF-B and PDGF-A mRNA expression in particular were significantly upregulated in Dupuytren's fibroblasts and were strongly induced by TGF-β3 treatment (Figure 4D and data not shown). SB-431542 compound or BMP6 counteracted the TGF-β-induced increase in PDGF-B mRNA expression (Figure 4D).
Targeting of TGF-β type I receptor and ERK1/2/MAP kinase pathways in Dupuytren's fibroblasts
We next set out to determine whether the elevated TGF-β/Smad and MAP kinase signalling pathways were causally linked to an increase in the expression of key fibrotic and proliferation proteins by interfering with these pathways using the ALK4, ALK5 and ALK7 inhibitor SB-431542 [8, 30], the MEK1 inhibitor PD98059  and BMP6. Treatment of Dupuytren's fibroblasts with SB-431542 completely inhibited elevated basal P-Smad2 levels and also attenuated P-ERK1/2 levels. This suggests that these increased basal activities are due to TGF-β or TGF-β-like ligands that are secreted by Dupuytren's fibroblasts themselves. PD98059 also strongly inhibited elevated basal P-ERK1/2 levels and had no significant effect on P-Smad2 levels (Figure 5A). Both treatments were associated with decreased expression of fibrotic marker proteins such as COL1 and α-SMA and reduced expression of the proliferation marker c-myc proto-oncogene (Figure 5A). Both SB-431542 and PD98059 treatment also inhibited COL1A2, CTGF and PAI-1 gene expression (Additional file 3, Supplementary Figure 3). The inhibitory effects of SB-431542 or PD98059 were potentiated by cotreatment with BMP6 (Figure 5A). Cotreatment with SB-431542/BMP6 and PD98059/BMP6 combinations decreased the levels of P-ERK1/2, COL1 and α-SMA to undetectable levels in Dupuytren's cells, which also was seen in untreated control cells. The c-myc level was significantly downregulated by PD98059/BMP6 and reached the low levels observed in control cells (Figure 5A).
We found that TGF-β3 strongly induced PDGF (Figure 4D), which, via its receptor, can activate ERK1/2/MAP kinase signalling. To determine the role of PDGF signalling in the augmented ERK1/2 phosphorylation observed in DD, we treated Dupuytren's fibroblasts with a selective PDGF receptor tyrosine kinase inhibitor (STI571, also known as imatinib mesylate)  and compared its effect with the effects of the inhibitors SB-431542 and PD98059. EGF receptor and VEGF receptor tyrosine kinase inhibitors [37, 38] were used as specificity controls for the PDGF receptor kinase inhibitor. The PDGF receptor kinase inhibitor led to strong but incomplete decreases in ERK1/2 phosphorylation and c-myc expression (Figure 5B). Its effect was weaker than cotreatment of Dupuytren's fibroblasts with SB-431542 and PD98059. The EGF and VEGF receptor kinase inhibitors showed only minor effects. We could find no significant inhibition of the elevated α-SMA expression upon challenge of Dupuytren's fibroblasts with STI561 (Figure 5B), however, which is consistent with previous findings that link PDGF to proliferation and not to a myofibroblast transdifferentiation response .
The inhibitory effects of PD98059 suggest that the ERK1/2 MAP kinase pathway plays an important role in the increased fibrotic characteristics of Dupuytren's fibroblasts compared to control fibroblasts. When we stimulated Dupuytren's fibroblasts with TPA, which activates ERK1/2/MAP kinase pathways (as well as other pathways), we found elevated α-SMA expression and collagen contraction (Additional file 4, Supplementary Figure 4). Thus, ERK/MAP kinase signalling may be sufficient to weakly mediate the fibroproliferative properties observed in Dupuytren's fibroblasts.
Taken together, our results indicate that both the TGF-β/Smad and ERK1/2 MAP kinase signalling pathways contribute to the fibrogenic responses of Dupuytren's fibroblasts. We therefore determined whether we could normalise the fibroproliferative characteristics of Dupuytren's fibroblasts by targeting TGF-β-like signalling and ERK1/2/MAP kinase with SB-431542 and the MEK1 inhibitor PD98059, respectively. Concurrent treatment of Dupuytren's fibroblasts with SB-431542 and PD98059 abrogated ERK1/2 phosphorylation as well as α-SMA and c-myc expression (Figure 5B). Consistent with this observation, we found that treatment with SB-431542 and/or PD98059 strongly inhibited the elevated basal proliferation of Dupuytren's fibroblasts and had only minor effects on the proliferation rate of normal fibroblasts (Figure 5C and Additional file 5, Supplementary Figure 5). The high spontaneous contraction rate in Dupuytren's fibroblasts was completely blocked by cotreatment with SB431542 and PD98059 (Figure 5D).
DD is a chronic, fibroproliferative disorder that is most likely induced by overactive cytokines such as TGF-β, which is thought to play a prominent role by stimulating Dupuytren's fibroblasts to produce excessive levels of ECM proteins and by promoting their contractile phenotype . In line with the results of previous studies, we found that biopsies and fibroblasts derived from primary cultures from affected areas in patients with DD had elevated expression levels of TGF-β, in particular the TGF-β1 and TGF-β3 isoforms, and that this correlated with increases in the expression levels of SMA, CTGF, fibronectin and collagen in Dupuytren's fibroblasts compared to controls [18, 21].
TGF-β can signal via the Smad signalling pathways. We observed that patients with DD showed elevated expression of Smad2 and Smad3, but not Smad1. Of note, whereas P-Smad2 levels were found to be elevated, this was not clear for P-Smad3 levels. Smad2 and Smad3 may have distinct roles. In a recent article, investigators demonstrated that Smad3 is a negative regulator of α-SMA expression and the activation of the myogenic program in the epithelium . When we challenged Dupuytren's fibroblasts with SB-431542, which inhibits TGF-β-like signalling pathways, the expression of key fibrotic markers such as PAI-1, CTGF, α-SMA and COL1 was decreased. Previous characterisation of the promoters of these target genes showed that they are regulated in a Smad-dependent manner [41, 42]. Moreover, application of SB-431542 revealed that the high amount of spontaneous contraction of Dupuytren's fibroblasts, when embedded in a collagen lattice, was caused by overactive TGF-β-like signalling. TGF-β receptor kinase inhibitors have been shown to inhibit fibrotic responses in other cells in vitro and in vivo.
In recent years, a strong link has been established between TGF-β-induced fibrosis and BMP expression and signalling. Challenging the fibrogenic properties of Dupuytren's fibroblasts with BMP6 inhibited the gene expression of TGF-β1 and TGF-β3 and their respective downstream Smad2 and Smad3 effectors. Whereas previous studies attributed antifibrotic effects to BMP7, a close homolog of BMP6 , we were unable to demonstrate this for Dupuytren's fibroblasts. One could speculate whether BMP6 could compete with TGF-β for the recruitment of distinct receptors, thereby limiting TGF-β activity. Our data suggest a novel level of cross-talk, as previous studies have suggested that BMPs had an inhibitory effect on the TGF-β/Smad pathway through the formation of mixed Smad1/5-Smad2/3 complexes [43, 44]. It is interesting that BMP6 in particular had an antagonising effect on TGF-β-driven DD, because it has been shown that myofibroblast progenitor cells derived from patients with diabetes are deficient in BMP6 expression , and there is some evidence of a relationship between diabetes and DD . In another study, BMP6 and BMP7 were found to have differential effects on chemotaxis via a Smad4-independent, phosphoinositide 3-kinase-dependent pathway . It would be worthwhile to explore whether similar mechanisms are of relevance in Dupuytren's fibroblasts. Although BMP6 may inhibit fibrotic responses, in discussing it as a potential therapeutic agent, one needs to take into account BMP6's action on normal fibroblasts and its strong osteoinductive properties .
The elevated ERK1/2 MAP kinase pathway could be linked to the elevated fibroproliferative characteristics of Dupuytren's fibroblasts. Treatment of cells with PD98059 inhibited the expression of fibrotic and proliferation markers. A role for MAP kinase signalling, also in cooperation with the Smad pathway, has been described for many TGF-β target genes [49–52]. In line with its potent inhibitory effects on fibroproliferative markers, spontaneous collagen contraction and elevated proliferation were inhibited by PD98059. Moreover, the finding that TPA induced ERK1/2 phosphorylation and collagen contraction suggests that activation of this pathway may be sufficient to induce contraction. BMP6 was not able to counteract this TPA-induced ERK response, which is in line with its proposed inhibitory actions further upstream at the level of TGF-β and Smad expression. Consistent with our results, inhibition of ERK1/2 MAP kinase signalling has been shown to mitigate fibrotic responses in scleroderma [53, 54]. Our observations suggest a role for elevated PDGF signalling in promoting the proliferation of Dupuytren's fibroblasts. Of note, overactive PDGF signalling has been implicated in fibrosis in multiple tissues [55–57], and treatment with PDGF receptor kinase inhibitors has been shown to inhibit fibrosis [58, 59].
Importantly, when both TGF-β receptors and ERK1/2 pathways were inhibited in Dupuytren's fibroblasts through simultaneous application of SB-431542 and PD98059, a complete block of the elevated basal proliferation and contraction was observed, which in turn commuted the Dupuytren's fibroblast phenotype into 'normal' fibroblasts.
Both the TGF-β and ERK1/2 MAP kinase pathways cooperated in mediating the enhanced proliferation and high spontaneous contraction of Dupuytren's fibroblasts. Taken together, our data indicate that the TGF-β/Smad and ERK1/2 MAP kinase pathways are prime targets for the development of nonsurgical intervention strategies to treat patients with DD. For example, concurrent topical application of inhibitors such as SB-431542 and PD98059 into the DD area could block fibroproliferative responses and recurrence in DD while preventing the potential problems associated with systemic administration of such compounds (schematically represented in Figure 6).
Bovine Serum Albumin
Dulbecco's Modified Eagle's Medium
- H & E:
Haematoxylin and Eosin Stain
Polymerase Chain Reaction.
We are grateful to K Iwata (OSI Pharmaceuticals), K Sampath (Creative BioMolecules) and Novartis for reagents. The authors acknowledge the Department of Plastic Surgery (Academisch Medisch Centrum (AMC), Amsterdam, The Netherlands) for providing the tissue material used in this project. We thank Jos Mulder (Department of Pathology, AMC) and Wicky Tigchelaar (Department of Cell Biology and Histology, AMC) for help with cell culture and α-SMA immunocytohistochemistry and Giorgio Perino and Stephen Doty (Hospital for Special Surgery, New York, NY, USA) for help with TGF-β3 and P-Smad2 immunohistochemistry. We appreciate the statistical support provided by Karen Ruschke (Freie Universität Berlin, Berlin Germany). This project was funded by the Dutch Organization for Scientific Research (NWO 918.66.606), the Netherlands Initiative for Regenerative Medicine, the Centre for Biomedical Genetics, the Marti-Keuning Eckhardt Stichting and the German Diabetes Society.
- Shaw RB, Chong AK, Zhang A, Hentz VR, Chang J: Dupuytren's disease: history, diagnosis, and treatment. Plast Reconstr Surg. 2007, 120: 44e-54e. 10.1097/01.prs.0000278455.63546.03.View ArticlePubMed
- Rayan GM: Dupuytren disease: anatomy, pathology, presentation, and treatment. J Bone Joint Surg Am. 2007, 89: 189-198.PubMed
- Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G: The myofibroblast: one function, multiple origins. Am J Pathol. 2007, 170: 1807-1816. 10.2353/ajpath.2007.070112.PubMed CentralView ArticlePubMed
- Tomasek JJ, Vaughan MB, Haaksma CJ: Cellular structure and biology of Dupuytren's disease. Hand Clin. 1999, 15: 21-34.PubMed
- Gabbiani G, Majno G: Dupuytren's contracture: fibroblast contraction? Ultrastructural study. Am J Pathol. 1972, 66: 131-146.PubMed CentralPubMed
- Kloen P: New insights in the development of Dupuytren's contracture: a review. Br J Plast Surg. 1999, 52: 629-635. 10.1054/bjps.1999.3187.View ArticlePubMed
- Heldin CH, Miyazono K, ten Dijke P: TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature. 1997, 390: 465-471. 10.1038/37284.View ArticlePubMed
- Inman GJ, Nicolás FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS: SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 2002, 62: 65-74. 10.1124/mol.62.1.65.View ArticlePubMed
- Derynck R, Zhang YE: Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature. 2003, 425: 577-584. 10.1038/nature02006.View ArticlePubMed
- Moustakas A, Heldin CH: Non-Smad TGF-β signals. J Cell Sci. 2005, 118: 3573-3584. 10.1242/jcs.02554.View ArticlePubMed
- Hinz B: Formation and function of the myofibroblast during tissue repair. J Invest Dermatol. 2007, 127: 526-537. 10.1038/sj.jid.5700613.View ArticlePubMed
- Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA: Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. 2002, 3: 349-363. 10.1038/nrm809.View ArticlePubMed
- Vaughan MB, Howard EW, Tomasek JJ: Transforming growth factor-β1 promotes the morphological and functional differentiation of the myofibroblast. Exp Cell Res. 2000, 257: 180-189. 10.1006/excr.2000.4869.View ArticlePubMed
- Kloen P, Jennings CL, Gebhardt MC, Springfield DS, Mankin HJ: Transforming growth factor-β: possible roles in Dupuytren's contracture. J Hand Surg Am. 1995, 20: 101-108. 10.1016/S0363-5023(05)80067-X.View ArticlePubMed
- Badalamente MA, Sampson SP, Hurst LC, Dowd A, Miyasaka K: The role of transforming growth factor β in Dupuytren's disease. J Hand Surg Am. 1996, 21: 210-215. 10.1016/S0363-5023(96)80102-X.View ArticlePubMed
- Baird KS, Crossan JF, Ralston SH: Abnormal growth factor and cytokine expression in Dupuytren's contracture. J Clin Pathol. 1993, 46: 425-428. 10.1136/jcp.46.5.425.PubMed CentralView ArticlePubMed
- Zamora RL, Heights R, Kraemer BA, Erlich HP, Groner JP: Presence of growth factors in palmar and plantar fibromatoses. J Hand Surg Am. 1994, 19: 435-441. 10.1016/0363-5023(94)90058-2.View ArticlePubMed
- Berndt A, Kosmehl H, Mandel U, Gabler U, Luo X, Celeda D, Zardi L, Katenkamp D: TGFβ and bFGF synthesis and localization in Dupuytren's disease (nodular palmar fibromatosis) relative to cellular activity, myofibroblast phenotype and oncofetal variants of fibronectin. Histochem J. 1995, 27: 1014-1020.View ArticlePubMed
- Wong M, Mudera V: Feedback inhibition of high TGF-β1 concentrations on myofibroblast induction and contraction by Dupuytren's fibroblasts. J Hand Surg Br. 2006, 31: 473-483. 10.1016/j.jhsb.2006.05.007.View ArticlePubMed
- Bisson MA, Beckett KS, McGrouther DA, Grobbelaar AO, Mudera V: Transforming growth factor-β1 stimulation enhances Dupuytren's fibroblast contraction in response to uniaxial mechanical load within a 3-dimensional collagen gel. J Hand Surg Am. 2009, 34: 1102-1110. 10.1016/j.jhsa.2009.02.008.View ArticlePubMed
- Tse R, Howard J, Wu Y, Gan BS: Enhanced Dupuytren's disease fibroblast populated collagen lattice contraction is independent of endogenous active TGF-β2. BMC Musculoskelet Disord. 2004, 5: 41-10.1186/1471-2474-5-41.PubMed CentralView ArticlePubMed
- Bisson MA, McGrouther DA, Mudera V, Grobbelaar AO: The different characteristics of Dupuytren's disease fibroblasts derived from either nodule or cord: expression of α-smooth muscle actin and the response, to stimulation by TGF-β1. J Hand Surg Br. 2003, 28: 351-356. 10.1016/S0266-7681(03)00135-9.View ArticlePubMed
- Bisson MA, Mudera V, McGrouther A, Grobbelaar AO: The contractile properties and responses to tensional loading of Dupuytren's disease-derived fibroblasts are altered: a cause of the contracture?. Plast Reconstr Surg. 2004, 113: 611-621. 10.1097/01.PRS.0000101527.76293.F1.View ArticlePubMed
- Gressner OA, Gressner AM: Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases. Liver Int. 2008, 28: 1065-1079. 10.1111/j.1478-3231.2008.01826.x.View ArticlePubMed
- Leask A, Parapuram SK, Shi-Wen X, Abraham DJ: Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease?. J Cell Commun Signal. 2009, 3: 89-94. 10.1007/s12079-009-0037-7.PubMed CentralView ArticlePubMed
- Battegay EJ, Raines EW, Seifert RA, Bowen-Pope D, Ross R: TGF-β induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell. 1990, 63: 515-524. 10.1016/0092-8674(90)90448-N.View ArticlePubMed
- Shin SS, Liu C, Chang EY, Carlson CS, Di Cesare PE: Expression of bone morphogenetic proteins by Dupuytren's fibroblasts. J Hand Surg Am. 2004, 29: 809-814. 10.1016/j.jhsa.2004.02.008.View ArticlePubMed
- Weiskirchen R, Meurer SK, Gressner OA, Herrmann J, Borkham-Kamphorst E, Gressner AM: BMP-7 as antagonist of organ fibrosis. Front Biosci. 2009, 14: 4992-5012. 10.2741/3583.View Article
- Petersen M, Thorikay M, Deckers M, van Dinther M, Grygielko ET, Gellibert F, de Gouville AC, Huet S, ten Dijke P, Laping NJ: Oral administration of GW788388, an inhibitor of TGF-β type I and II receptor kinases, decreases renal fibrosis. Kidney Int. 2008, 73: 705-715. 10.1038/sj.ki.5002717.View ArticlePubMed
- Grinell F, Ho CH: Transforming growth factor β stimulates fibroblast-collagen matrix contraction by different mechanisms in mechanically loaded and unloaded matrices. Exp Cell Res. 2002, 273: 248-255. 10.1006/excr.2001.5445.View Article
- Hinz B, Celetta G, Tomasek JJ, Gabbiani G, Chaponnier C: α-smooth muscle actin expression upregulates fibroblast contractile activity. Mol Biol Cell. 2001, 12: 2730-2741.PubMed CentralView ArticlePubMed
- Rayan GM, Tomasek JJ: Generation of contractile force by cultured Dupuytren's disease and normal palmar fibroblasts. Tissue Cell. 1994, 26: 747-756. 10.1016/0040-8166(94)90057-4.View ArticlePubMed
- Augoff K, Kula J, Gosk J, Rutowski R: Epidermal growth factor in Dupuytren's disease. Plast Reconstr Surg. 2005, 115: 128-133.PubMed
- Baird KS, Crossan JF, Ralston SH: Abnormal growth factor and cytokine expression in Dupuytren's contracture. J Clin Pathol. 1993, 46: 425-428. 10.1136/jcp.46.5.425.PubMed CentralView ArticlePubMed
- Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR: PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem. 1995, 270: 27489-27494. 10.1074/jbc.270.46.27489.View ArticlePubMed
- Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG, Druker BJ: CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood. 1997, 90: 4947-4952.PubMed
- Solorzano CC, Baker CH, Tsan R, Traxler P, Cohen P, Buchdunger E, Killion JJ, Fidler IJ: Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma. Clin Cancer Res. 2001, 7: 2563-2572.PubMed
- Ozaki H, Seo MS, Ozaki K, Yamada H, Yamada E, Okamoto N, Hofmann F, Wood JM, Campochiaro PA: Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol. 2000, 156: 697-707. 10.1016/S0002-9440(10)64773-6.PubMed CentralView ArticlePubMed
- Dandré F, Owens GK: Platelet-derived growth factor-BB and Ets-1 transcription factor negatively regulate transcription of multiple smooth muscle cell differentiation marker genes. Am J Physiol Heart Circ Physiol. 2004, 286: H2042-2051. 10.1152/ajpheart.00625.2003.View ArticlePubMed
- Masszi A, Speight P, Charbonney E, Lodyga M, Nakano H, Szászi K, Kapus A: Fate-determining mechanisms in epithelial-myofibroblast transition: major inhibitory role for Smad3. J Cell Biol. 2010, 188: 383-399. 10.1083/jcb.200906155.PubMed CentralView ArticlePubMed
- Vindevoghel L, Lechleider RJ, Kon A, de Caestecker MP, Uitto J, Roberts AB, Mauviel A: SMAD3/4-dependent transcriptional activation of the human type VII collagen gene (COL7A1) promoter by transforming growth factor β. Proc Natl Acad Sci USA. 1998, 95: 14769-1474. 10.1073/pnas.95.25.14769.PubMed CentralView ArticlePubMed
- Deckers M, van Dinther M, Buijs J, Que I, Löwik C, van der Pluijm G, ten Dijke P: The tumor suppressor Smad4 is required for transforming growth factor β-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res. 2006, 66: 2202-2209. 10.1158/0008-5472.CAN-05-3560.View ArticlePubMed
- Goumans MJ, Valdimarsdottir G, Itoh S, Lebrin F, Larsson J, Mummery C, Karlsson S, ten Dijke P: Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFβ/ALK5 signaling. Mol Cell. 2003, 12: 817-828. 10.1016/S1097-2765(03)00386-1.View ArticlePubMed
- Daly AC, Randall RA, Hill CS: Transforming growth factor β-induced Smad1/5 phosphorylation in epithelial cells is mediated by novel receptor complexes and is essential for anchorage-independent growth. Mol Cell Biol. 2008, 28: 6889-6902. 10.1128/MCB.01192-08.PubMed CentralView ArticlePubMed
- Nguyen TQ, Chon H, van Nieuwenhoven FA, Braam B, Verhaar MC, Goldschmeding R: Myofibroblast progenitor cells are increased in number in patients with type 1 diabetes and express less bone morphogenetic protein 6: a novel clue to adverse tissue remodelling?. Diabetologia. 2006, 49: 1039-1048. 10.1007/s00125-006-0172-0.View ArticlePubMed
- Noble J, Heathcote JG, Cohen H: Diabetes mellitus in the aetiology of Dupuytren's disease. J Bone Joint Surg Br. 1984, 66: 322-325.PubMed
- Perron JC, Dodd J: ActRIIA and BMPRII type II BMP receptor subunits selectively required for Smad4-independent BMP7-evoked chemotaxis. PLoS One. 2009, 4: e8198-10.1371/journal.pone.0008198.PubMed CentralView ArticlePubMed
- Song K, Krause C, Shi S, Patterson M, Suto R, Grgurevic L, Vukicevic S, van Dinther M, Falb D, ten Dijke P, Alaoui-Ismaili MH: Identification of a key residue mediating bone morphogenetic protein (BMP)-6 resistance to noggin inhibition allows for engineered BMPs with superior agonist activity. J Biol Chem. 2010, 285: 12169-12180. 10.1074/jbc.M109.087197.PubMed CentralView ArticlePubMed
- Javelaud D, Mauviel A: Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-β: implications for carcinogenesis. Oncogene. 2005, 24: 5742-5750. 10.1038/sj.onc.1208928.View ArticlePubMed
- Chen Y, Blom IE, Sa S, Goldschmeding R, Abraham DJ, Leask A: CTGF expression in mesangial cells: involvement of SMADs, MAP kinase, and PKC. Kidney Int. 2002, 62: 1149-1159. 10.1111/j.1523-1755.2002.kid567.x.View ArticlePubMed
- Leask A, Holmes A, Black CM, Abraham DJ: Connective tissue growth factor gene regulation: requirements for its induction by transforming growth factor-β2 in fibroblasts. J Biol Chem. 2003, 278: 13008-13015. 10.1074/jbc.M210366200.View ArticlePubMed
- Guo B, Inoki K, Isono M, Mori H, Kanasaki K, Sugimoto T, Akiba S, Sato T, Yang B, Kikkawa R, Kashiwagi A, Haneda M, Koya D: MAPK/AP-1-dependent regulation of PAI-1 gene expression by TGF-β in rat mesangial cells. Kidney Int. 2005, 68: 972-984. 10.1111/j.1523-1755.2005.00491.x.View ArticlePubMed
- Stratton R, Rajkumar V, Ponticos M, Nichols B, Shiwen X, Black CM, Abraham DJ, Leask A: Prostacyclin derivatives prevent the fibrotic response to TGF-β by inhibiting the Ras/MEK/ERK pathway. FASEB J. 2002, 16: 1949-1951.PubMed
- Bhattacharyya S, Chen SJ, Wu M, Warner-Blankenship M, Ning H, Lakos G, Mori Y, Chang E, Nihijima C, Takehara K, Feghali-Bostwick C, Varga J: Smad-independent transforming growth factor-β regulation of early growth response-1 and sustained expression in fibrosis: implications for scleroderma. Am J Pathol. 2008, 173: 1085-1099. 10.2353/ajpath.2008.080382.PubMed CentralView ArticlePubMed
- Leask A: Potential therapeutic targets for cardiac fibrosis: TGFβ, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res. 2010, 106: 1675-1680. 10.1161/CIRCRESAHA.110.217737.View ArticlePubMed
- Trojanowska M: Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology (Oxford). 2008, 47 (Suppl 5): v2-v4.View Article
- Bonner JC: Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev. 2004, 15: 255-273. 10.1016/j.cytogfr.2004.03.006.View ArticlePubMed
- Levitzki A: PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases. Cytokine Growth Factor Rev. 2004, 15: 229-235. 10.1016/j.cytogfr.2004.03.010.View ArticlePubMed
- Distler JH, Distler O: Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies. Ann Rheum Dis. 2010, 69 (Suppl 1): i48-i51. 10.1136/ard.2009.120196.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.